Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

Bertram Pitt; Lars Kober; Piotr Ponikowski; Mihai Gheorghiade; Gerasimos Filippatos; Henry Krum; Christina Nowack; Peter Kolkhof; So-Young Kim; Faiez Zannad

doi:10.1093/eurheartj/eht187

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

Bertram Pitt, Lars Kober, Piotr Ponikowski, Mihai Gheorghiade, Gerasimos Filippatos, Henry Krum, Christina Nowack, Peter Kolkhof, So-Young Kim, Faiez Zannad

536 Citationer (Scopus)

Abstract

Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients with heart failure and reduced left ventricular ejection fraction (HFrEF), but their use is limited by hyperkalaemia and/or worsening renal function (WRF). BAY 94-8862 is a highly selective and strongly potent non-steroidal MRA. We investigated its safety and tolerability in patients with HFrEF associated with mild or moderate chronic kidney disease (CKD).

Originalsprog	Engelsk
Tidsskrift	European Heart Journal
Vol/bind	34
Udgave nummer	31
Sider (fra-til)	2453-63
Antal sider	11
ISSN	0195-668X
DOI	https://doi.org/10.1093/eurheartj/eht187
Status	Udgivet - aug. 2013

Adgang til dokumentet

10.1093/eurheartj/eht187

Fingeraftryk

Dyk ned i forskningsemnerne om 'Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Pitt, B., Kober, L., Ponikowski, P., Gheorghiade, M., Filippatos, G., Krum, H., Nowack, C., Kolkhof, P., Kim, S.-Y., & Zannad, F. (2013). Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal, 34(31), 2453-63. https://doi.org/10.1093/eurheartj/eht187

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. / Pitt, Bertram; Kober, Lars; Ponikowski, Piotr et al.
I: European Heart Journal, Bind 34, Nr. 31, 08.2013, s. 2453-63.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Pitt, B, Kober, L, Ponikowski, P, Gheorghiade, M, Filippatos, G, Krum, H, Nowack, C, Kolkhof, P, Kim, S-Y & Zannad, F 2013, 'Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial', European Heart Journal, bind 34, nr. 31, s. 2453-63. https://doi.org/10.1093/eurheartj/eht187

Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. European Heart Journal. 2013 aug.;34(31):2453-63. doi: 10.1093/eurheartj/eht187

@article{6a604961b95641e8a0552302793e9474,

title = "Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial",

abstract = "Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients with heart failure and reduced left ventricular ejection fraction (HFrEF), but their use is limited by hyperkalaemia and/or worsening renal function (WRF). BAY 94-8862 is a highly selective and strongly potent non-steroidal MRA. We investigated its safety and tolerability in patients with HFrEF associated with mild or moderate chronic kidney disease (CKD).",

author = "Bertram Pitt and Lars Kober and Piotr Ponikowski and Mihai Gheorghiade and Gerasimos Filippatos and Henry Krum and Christina Nowack and Peter Kolkhof and So-Young Kim and Faiez Zannad",

year = "2013",

month = aug,

doi = "10.1093/eurheartj/eht187",

language = "English",

volume = "34",

pages = "2453--63",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "31",

}

TY - JOUR

T1 - Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease

T2 - a randomized, double-blind trial

AU - Pitt, Bertram

AU - Kober, Lars

AU - Ponikowski, Piotr

AU - Gheorghiade, Mihai

AU - Filippatos, Gerasimos

AU - Krum, Henry

AU - Nowack, Christina

AU - Kolkhof, Peter

AU - Kim, So-Young

AU - Zannad, Faiez

PY - 2013/8

Y1 - 2013/8

N2 - Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients with heart failure and reduced left ventricular ejection fraction (HFrEF), but their use is limited by hyperkalaemia and/or worsening renal function (WRF). BAY 94-8862 is a highly selective and strongly potent non-steroidal MRA. We investigated its safety and tolerability in patients with HFrEF associated with mild or moderate chronic kidney disease (CKD).

AB - Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients with heart failure and reduced left ventricular ejection fraction (HFrEF), but their use is limited by hyperkalaemia and/or worsening renal function (WRF). BAY 94-8862 is a highly selective and strongly potent non-steroidal MRA. We investigated its safety and tolerability in patients with HFrEF associated with mild or moderate chronic kidney disease (CKD).

U2 - 10.1093/eurheartj/eht187

DO - 10.1093/eurheartj/eht187

M3 - Journal article

C2 - 23713082

SN - 0195-668X

VL - 34

SP - 2453

EP - 2463

JO - European Heart Journal

JF - European Heart Journal

IS - 31

ER -